We read through the 45-page congressional investigation into Biogen's Alzheimer's drug. Here are the 3 most shocking takeaways.

Dec 29 2022 by Business Insider

 
The Biogen headquarters in Cambridge, Mass.

AP Photo/Steven Senne

A Congressional investigation into Biogen's controversial Alzheimer's drug Aduhlem was just released. The 45-page report details an improper relationship between the company and the FDA. Here are three of the most surprising takeaways. 

Aduhelm, the first Alzheimer's drug to be approved by the Food and Drug Administration in 18 years, has already faced its share of controversy. On Thursday an 18-month congressional...

Continue Reading We read through the 45-page congressional investigation into Biogen's Alzheimer's drug. Here are the 3 most shocking takeaways.